Onco-Summaries: Daily Oncology Updates at a Glance

17/06/2026

---

• Avenacy Launches Bortezomib for Injection in the U.S., Marking Its 28th Product Since Inception

---

Avenacy Launches Bortezomib for Injection in the U.S., Marking Its 28th Product Since Inception (Ref)

Avenacy has officially launched Bortezomib for Injection in the US, a generic equivalent of VELCADE® indicated for adults with multiple myeloma and mantle cell lymphoma

The product is available as a 3.5 mg single-dose vial and features Avenacy's differentiated packaging and labeling to support accurate medication selection and patient safety

Return to Top